Ginkgo biloba extract egb 761« in the treatment of dementia: Evidence of efficacy and tolerability;Ginkgo-Spezialextrakt EGb 761« in der Behandlung der Demenz: Evidenz für Wirksamkeit und Verträglichkeit

Fortschritte der Neurologie Psychiatrie

Volumn 77, Issue 9, 2009, Pages 494-506

  Kasper, S ^a   Schubert, H ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Psychiatrisches Krankenhaus Hall ^*  (Austria)

Author keywords

Alzheimer's disease; Dementia; EGb 761; Ginkgo biloba; Review; Vascular dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GINKGO BILOBA EXTRACT; PLACEBO; CARDIOVASCULAR AGENT; GINKGO BILOBA EXTRACT 761; PLANT EXTRACT;

CLINICAL TRIAL; COGNITION; DEMENTIA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; OUTCOME ASSESSMENT; REVIEW; TASK PERFORMANCE; TREATMENT RESPONSE; AGED; META ANALYSIS; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR AGENTS; DEMENTIA; HUMANS; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 70350462942     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0028-1109504     Document Type: Review

References (70)

1. Barth S A., Inselmann G, Engemann R, et al. Influences of Ginkgo biloba on Cyclosporin A induced lipid peroxidation in human liver microsomes in comparison to vitamin E, Glutathione and N-Acetylcysteine. Biochem Pharmacol 1991 41 1521-1526
2. Dumont E, Petit E, Tarrade T, et al. UV-C irradiation-induced peroxidative degradation of microsomal fatty acids and proteins: protection by an extract of Ginkgo biloba (EGb 761). Free Radic Biol Med 1992 13 197-203
3. Karcher L, Zagermann P, Krieglstein J. Effects of an extract of Ginkgo biloba on rat brain energy metabolism in hypoxia. Naunyn-Schmiedebergs Arch Pharmacol 1984 327 31-35
4. Spinnewyn B, Blavet N, Clostre F. Effets de lextrait de Ginkgo biloba sur un modèle dischémie cérébrale chez la gerbille. Presse Med 1986 15 1511-1515
5. Sastre J, Millán A, García d la Asunción J, et al. A Ginkgo biloba extract (EGb 761«) prevents mitochondrial aging by protecting against oxidative stress. Free Radic Biol Med 1998 24 298-304
6. Eckert A, Keil U, Kressmann S, et al. Effects of EGb 761« Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry 2003 36 (Suppl 1) S15-S23
7. Hoyer S, Lannert H, Nöldner M, et al. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J Neural Transm 1999 106 1171-1188
8. Luo Y, Smith J V., Paramasivam V, et al. Inhibition of amyloid- aggregation and caspase-3 activation by the Ginkgo biloba extract EGb 761«. Proc Natl Acad Sci U S A 2002 99 12197-12202
9. Wu Y, Wu Z, Butko P, et al. Amyloid - induced pathological behaviours are suppressed by Ginkgo biloba extract EGb 761« and ginkgolides in transgenic Caenorhabditis elegans. J Neurosc 2006 26 13102-13113
10. Bastianetto S, Ramassamy C, Doré S, et al. The Ginkgo biloba extract (EGb 761«) protects hippocampal neurons against cell death induced by ß-amyloid. Eur J Neurosci 2000 12 1882-1890
11. Smith J V., Luo Y. Elevation of oxidative free radicals in Alzheimers disease models can be attenuated by Ginkgo biloba extract EGb 761«. J Alzheimers Dis 2003 5 287-300
12. Taylor J E. The effects of chronic, oral Ginkgo biloba extract administration on neurotransmitter receptor binding in young and aged Fisher 344 rats. Agnoli A, Rapin J R, Scapagnini V, Weitbrecht WU Effects of Ginkgo Biloba Extract on Organic Cerebral Impairment Montrouge John Libbey Eurotext 1985 31-34
13. Huguet F, Drieu K, Piriou A. Decreased cerebral 5-HT1A receptors during aging: reversal by Ginkgo biloba Extract (EGb 761). J Pharm Pharmacol 1994 46 316-318
14. Kritofiková Z, Beneová O, Tejkalová H. Changes of high-affinity choline uptake in the hippocampus of old rats after long-term administration of two nootropic drugs (Tacrine and Ginkgo biloba extract). Dementia 1992 3 304-307
15. Winter E. Effects of an Extract of Ginkgo Biloba on Learning and Memory in Mice. Pharmacol Biochem Behav 1991 38 109-114
16. Rapin J R., Lamproglou I, Drieu K, et al. Demonstration of the anti-stress activity of an extract of Ginkgo biloba (EGb 761«) using a discrimination learning task. Gen Pharmacol 1994 25 1009-1016
17. Reddy P H., Beal M F. Are mitochondria critical in the pathogenesis of Alzheimers disease? Brain Res Rev 2005 49 618-632
18. Onyango I G., Khan S M. Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimers disease. Curr Alzheimer Res 2006 3 339-349
19. Monte S M., Wands J R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to Alzheimers disease. J Alzheimers Dis 2005 7 45-61
20. Razay G de la, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007 64 93-96
21. Hoozemans J JM, Chafekar S M., Baas F, et al. Always around, never the same: Pathways of amyloid beta induced neurodegeneration throughout the pathogenic cascade of Alzheimers disease. Curr Med Chem 2006 13 2599-2605
22. Klein W L. Synaptic targeting by A oligomers (ADDLS) as a basis for memory loss in early Alzheimers disease. Alzheimers Dement 2006 2 43-55
23. Walsh D M., Selkoe D J. A beta oligomers - a decade of discovery. J Neurochem 2007 101 1172-1184
24. Költringer P, Langsteger W, Ober O. Dose-dependent hemorheological effects and microcirulatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol 1995 15 649-656
25. Erdinçler D S., Karakoç Y, Toplan S, et al. The effect of Ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability. Clin Hemorheol 1996 16 271-276
26. Heiss W D., Zeiler K. Medikamentöse Beeinflussung der Hirndurchblutung. Pharmakotherapie 1978 1 137-144
27. Luthringer R, dArbigny P, Macher J P. Ginkgo biloba extract (EGb 761), EEG and event-related potentials. Christen Y, Courtois Y, Droy-Lefaix MT Advances in Ginkgo biloba extract research, vol. 4. Effects of Ginkgo biloba on aging and age-related disorders Paris Elsevier 1995 107-118
28. Itil T M., Eralp E, Tsambis E, et al. Central nervous system effects of Ginkgo biloba, a plant extract. Am J Ther 1996 3 63-73
29. Fourtillan J B., Brisson A M., Girault J, et al. Propriété pharmacocinétique du Bilobalide et des Ginkgolides A et B chez le sujet sain après administrations intraveineuses et orales dextrait de Ginkgo biloba (EGb 761«). Therapie 1995 50 137-144
30. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002 Issue 4. Art. No.: CD 003120
31. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2007 Issue 2. Art. No.: CD 003120
32. Napryeyenko O, Borzenko I, for the GINDEM-NP Study Group. Ginkgo biloba special extract in dementia with neuropsychiatric features. Arzneimittelforschung 2007 57 4-11
33. Napryeyenko O, Sonnik G, Tartakovsky I. Efficacy and tolerability of Ginkgo biloba extract EGb 761« by type of dementia: Analyses of a randomised controlled trial. J Neurol Sci 2009 doi: 10.1016/j.jns.2009.02.353
34. Schneider L S., DeKosky S T., Farlow M R., et al. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimers type. Curr Alzheimer Res 2005 2 541-551
35. Kanowski S, Herrmann W M., Stephan K, et al. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996 29 47-56
36. Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761« in dementia: Intent-to-treat analyses of a 24-week, multi-centre, double-blind, placebo-controlled, randomised trial. Pharmacopsychiatry 2003 36 297-303
37. Le Bars P L., Katz M M., Berman N, et al. A placebo-controlled, double-blind randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997 278 1327-1332
38. Le Bars P L., Kieser M, Itil K Z. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord 2000 11 230-237
39. Le Bars P L., Velasco F M., Ferguson J M., et al. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimers disease. Neuropsychobiology 2002 45 19-26
40. Maurer K, Ihl R, Dierks T, et al. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 1997 31 645-655
41. Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 1994 9 215-222
42. Mancini M, Agozzino B, Bompani R. Effetti clinico-terapeutici dellestratto di Ginkgo biloba (EGb) in confronto a placebo, nel trattamento di pazienti affetti da demenza psicorganica senile su base arteriosclerotica. Gazz Med Ital Arch Sci Med 1993 152 69-80
43. Weitbrecht W U., Jansen W. Primär degenerative Demenz: Therapie mit Ginkgo-biloba-Extrakt. Placebokontrollierte Doppelblind- und Vergleichsstudie. Fortschr Med 1986 104 199-202
44. Haase J, Halama P, Hörr R. Wirksamkeit kurzdauernder Infusionsbehandlungen mit Ginkgo-biloba-Spezialextrakt EGb 761« bei Demenz vom vaskulären und Alzheimer-Typ. Z Gerontol Geriat 1996 29 302-309
45. Yancheva S, Ihl R, Nikolova G, et al. Ginkgo biloba Extract EGb 761«, donepezil or both combined in the treatment of Alzheimers disease with neuropsychiatric features: A randomised, double-blind, exploratory trial. Aging Ment Health 2009 13 183-190
46. Leber P. Guidelines for the clinical evaluation of antidementia drugs. First draft. Rockville, MD US Food and Drug Administration 1990
47. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on medicinal products in the treatment of Alzheimers disease. London The European Agency for the Evaluation of Medicinal Products 1997
48. Ihl R, Grass-Kapanke B, Jänner M, et al. Neuropsychometric tests in cross sectional and longitudinal studies a regression analysis of ADAS-cog, SKT and MMSE. Pharmacopsychiatry 1999 32 248-354
49. Schneider L S., Olin J T., Lyness S A., et al. Eligibility of Alzheimers disease clinic patients for clinical trials. J Am Geriatr Soc 1997 45 923-928
50. Lyketsos C G., Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. Results from the Cardiovascular Health Study. JAMA 2002 288 1475-1483
51. Letzel H, Haan J, Feil W B. Nootropics: Efficacy and tolerability of products from three active substance classes. Journal of Drug Development and Clinical Practice 1996 8 77-94
52. Oken B S., Storzbach D M., Kaye J A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998 55 1409-1415
53. Ernst E, Pittler M H. Ginkgo biloba for dementia. A systematic review of double-blind, placebo-controlled trials. Clin Drug Investig 1999 17 301-308
54. IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ginkgohaltige Präparate bei Alzheimer Demenz. Abschlussbericht. Auftrag A 05 19B, Version 1.0. IQWiG IQWiG-Berichte Jahr: 2008 Nr.39 Köln IQWiG 2008 http://www.iqwig.de/download/A05 19B-Abschlussbericht-Ginkgohaltige-Praeparate-bei-Alzheimer-Demenz.pdf (Zugriff am 14.4.2009)
55. DeKosky S T., Williamson J D., Fitzpatrick A L., et al. Ginkgo biloba for prevention of dementia. A randomized controlled trial. JAMA 2008 300 2253-2262
56. Hoerr R. Treatment effects of EGb 761« and cholinesterase inhibitors why available studies do not demonstrate superiority of the latter. Phytomedicine 2005 12 598-600
57. Wettstein A. Cholinesterasehemmer und Ginkgoextrakte in der Demenztherapie vergleichbar? Fortschr Med 1999 117 11-18
58. Knapp M J., Knopman D S., Solomon P R., et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimers disease. JAMA 1994 271 985-991
59. Rogers S l, Farlow M R., Doody R S., et al. A 24 week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimers disease. Neurology 1998 50 136-145
60. Corey-Bloom J, Anand R, Veach for the ENA 713 B 352 Study Group J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimers disease. International Journal of Geriatric Psychopharmacology 1998 1 55-65
61. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimers disease: international randomised controlled trial. Br Med J 1999 318 633-640
62. Raskind M A., Peskind E R., Wessel T, et al. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000 54 2261-2268
63. Tariot P N., Solomon P R., Morris J C., et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000 54 2269-2276
64. Wilcock G K., Lilienfeld S, Gaens E, et al. Efficacy and safety of galantamine in patients with mild to moderate Alzheimers disease: multicentre randomised controlled trial. Br Med J 2000 321 1445-1449
65. Bandolier N N. Evidence based thinking about health care. Number needed to treat (NNT). Bandolier 59 January 1999 Accessible at http://www.jr2.ox.ac.uk/ bandolier/band59/NNT1.html. Last access 16.06.2009
66. Bullock R, Touchon J, Bergmann H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimers disease over a 2-year period. Curr Med Res Opin 2005 12 1317-1327
67. Bancher C, Croy A, Dal Bianco P, et al. Österreichisches Alzheimer-Krankheit-Konsensus. Neuropsychiatr, 1998 12 126-167
68. Alf C, Bancher C, Benke T, et al. Konsensusstatement Demenz der Österreichischen Alzheimer-Gesellschaft und der Österreichischen Alzheimer-Liga. Neuropsychiatr 2004 18 39-46 (Pubitemid 39648141)
69. Kasper S, Kalousek M, Saletu B, et al. Demenzerkrankungen Medikamentöse Therapie. Konsensus-Statement State of the Art 2006. CliniCum psy Sonderausgabe November 2006 Wien Medizin Medien Austria
70. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde DGPPN. Praxisleitlinien in Psychiatrie und Psychotherapie Band 3, Behandlungsleitlinie Demenz. Darmstadt Steinkopff 2000 26-29